2. Search Result
Search Result
Results for "

sb

" in MedChemExpress (MCE) Product Catalog:

339

Inhibitors & Agonists

2

Fluorescent Dyes

4

Biochemical Assay Reagents

4

Peptides

6

Inhibitory Antibodies

7

Natural
Products

7

Recombinant Proteins

11

Isotope-Labeled Compounds

13

Antibodies

1

Click Chemistry

1

Oligonucleotides

2

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10431
    SB-431542
    290+ Cited Publications

    		 Organoid TGF-β Receptor Apoptosis Cancer
    SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .
    SB-431542
  • HY-10295
    SB 202190
    130+ Cited Publications

    		 Organoid p38 MAPK Autophagy Apoptosis Neurological Disease Cancer
    SB 202190 is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 has anti-cancer activity and rescued memory deficits . SB202190 induces autophagy .
    SB 202190
  • HY-10966
    SB-590885
    5+ Cited Publications

    		 Raf Apoptosis Neurological Disease Metabolic Disease Cancer
    SB-590885 is a BRAF/c-Raf kinase inhibitor that selectively targets B-Raf, and it amplifies the ERK/MAPK signaling pathway in RAS-activated cells. SB-590885 effectively inhibits the malignant proliferation, transformation and tumorigenicity of oncogenic B-Raf cells; it also induces the proliferation of erythroid progenitor cells, delays their differentiation and promotes hemoglobin synthesis, thereby improving ineffective erythropoiesis and reducing apoptosis. SB-590885 exerts a synergistic effect with TGF-β inhibitors and glucocorticoids, significantly promoting the formation of erythroid colonies in cells from patients with Diamond-Blackfan anemia (DBA). SB-590885 is mainly used in relevant studies on DBA, cisplatin-induced myelosuppression-related anemia, and pan-cancers such as melanoma and colorectal cancer .
    SB-590885
  • HY-12354
    SB-3CT
    25+ Cited Publications

    		 MMP Cancer
    SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity .
    SB-3CT
  • HY-15370A
    SB-269970 hydrochloride
    5+ Cited Publications

    sb-269970A

    		 5-HT Receptor Neurological Disease
    SB-269970 hydrochloride is a potent, selective and brain-penetrant 5-HT7 receptor antagonist with a pKi of 8.3. SB-269970 hydrochloride exhibits >50-fold selectivity against other 5-HT receptors .
    SB-269970 hydrochloride
  • HY-10431G
    SB-431542

    		TGF-β Receptor Neurological Disease Cancer
    SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling .
    SB-431542
  • HY-107407
    SB-218078
    5 Publications Verification

    		 Checkpoint Kinase (Chk) CDK PKC Apoptosis Cancer
    SB-218078 is a potent, selective, ATP-competitive and cell-permeable checkpoint kinase 1 (Chk1) inhibitor that inhibits Chk1 phosphorylation of cdc25C with an IC50 of 15 nM. SB-218078 is less potently inhibits Cdc2 (IC50 of 250 nM) and PKC (IC50 of 1000 nM). SB-218078 causes apoptosis by DNA damage and cell cycle arrest .
    SB-218078
  • HY-12245
    SB-366791
    5+ Cited Publications

    		 TRP Channel Inflammation/Immunology
    SB-366791 is a potent and selective vanilloid receptor (VR1/TRPV1) antagonist (IC50=5.7 nM). SB-366791 can be used for the research of inflammation .
    SB-366791
  • HY-10895
    SB-334867
    5+ Cited Publications

    sb 334867A

    		 Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-334867 (SB 334867A) is an excellent,selective and blood-brain barrier permeable orexin-1 (OX1) receptor antagonist, shows selectivity over OX2 (pKb=7.4), 100-fold over 5-HT2B, 5-HT2C with pKi values of 5.4 and 5.3, respectively . SB-334867 reduces ethanol consumption and inhibits the acquisition of morphine-induced sensitization to locomotor activity in vivo .
    SB-334867
  • HY-101105A
    SB-224289 hydrochloride
    2 Publications Verification

    sb-224289A

    		 5-HT Receptor Neurological Disease
    SB-224289 hydrochloride is a selective 5-HT1B receptor antagonist, with anxiolytic effect.
    SB-224289 hydrochloride
  • HY-103363
    SB-328437
    3 Publications Verification

    		 CCR Thymidylate Synthase Inflammation/Immunology Cancer
    SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .
    SB-328437
  • HY-10295A
    SB 202190 hydrochloride
    130+ Cited Publications

    		 Organoid p38 MAPK Autophagy Apoptosis Neurological Disease Cancer
    SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .
    SB 202190 hydrochloride
  • HY-19307
    SB-273005

    		Integrin Interleukin Related Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
    SB-273005 is an orally active non-peptide αvβ3 integrin antagonist with Ki values of 1.2 nM and 0.3 nM for αvβ3 and αvβ5, respectively. SB-273005 blocks the binding of integrins to the RGD sequence in the extracellular matrix. SB-273005 inhibits Rictor phosphorylation and reduces IL-10 secretion. SB-273005 inhibits inflammation, prevents bone loss, regulates vascular smooth muscle function, and reverses pregnancy-induced immune deviation. SB-273005 can be used in the study of rheumatoid arthritis, osteoporosis, and aneurysms. .
    SB-273005
  • HY-15722
    SB-222200
    5+ Cited Publications

    		 Neurokinin Receptor Neurological Disease Endocrinology
    SB-222200 is a potent, selective, orally active and blood-brain barrier (BBB) penetrant NK-3 receptor antagonist. SB-222200 is developed for central nervous system (CNS) disorders .
    SB-222200
  • HY-108518
    SB-772077B dihydrochloride

    		ROCK Cardiovascular Disease Inflammation/Immunology
    SB-772077B dihydrochloride is an orally active aminofuran-based Rho kinase ((ROCK)) inhibitor with IC50 values of 5.6 nM and 6 nM for ROCK1 and ROCK2, respectively. SB-772077B dihydrochloride reduces inflammatory cytokines (TNF-α and IL-6). SB-772077B dihydrochloride relaxes aortic rings and lowers blood pressure. SB-772077B dihydrochloride can be used in the research of inflammatory diseases .
    SB-772077B dihydrochloride
  • HY-15370
    SB-269970
    5+ Cited Publications

    		 5-HT Receptor Neurological Disease
    SB-269970 is a potent, selective and brain-penetrant 5-HT7 receptor antagonist with a pKi of 8.3. SB-269970 exhibits >50-fold selectivity against other 5-HT receptors .
    SB-269970
  • HY-110313
    SB-747651A dihydrochloride
    1 Publications Verification

    		 p38 MAPK Inflammation/Immunology
    SB-747651A dihydrochloride is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC50 of 11 nM. SB-747651A dihydrochloride also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A dihydrochloride can be used for inflammation research .
    SB-747651A dihydrochloride
  • HY-10431R
    SB-431542 (Standard)

    		Apoptosis TGF-β Receptor Organoid Reference Standards Cancer
    SB-431542 (Standard) is the analytical standard of SB-431542. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI). SB-431542 has inhibitory activity for ALK4, ALK5 and ALK7 with IC50 values of 1 μM, 0.75 μM and 2 μM, respectively. SB-431542 also inhibits TGF-β-induced transcription, gene expression, apoptosis, and growth suppression. SB-431542 can be used for the research of cancer and signal transduction pathways .
    SB-431542 (Standard)
  • HY-18306
    SB 242235
    2 Publications Verification

    		 p38 MAPK Autophagy Cancer
    SB-242235 is a potent and selective p38 MAP kinase inhibitor, with an IC50 of 1.0　μM in primary human chondrocytes .
    SB 242235
  • HY-103100
    SB-699551
    1 Publications Verification

    		 5-HT Receptor Epigenetic Reader Domain Akt Ribosomal S6 Kinase (RSK) FOXO Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    SB-699551 is a selective and brain penetrant 5-HT5A receptor antagonist with a pKi of 8.2 nM. SB-699551 shows high selectivity over most other 5-HT receptor subtypes, dopamine receptors, and α1B adrenoceptor. SB-699551 disrupts Gαi/o-coupled and PI3K/AKT/mTOR signaling pathways, alters CREB, ATF1, AKT, PRAS40, S6K, and FOXO1 phosphorylation in breast tumor cells. SB-699551 can be used for the research of anxiety, breast cancer, and Alzheimer's disease .
    SB-699551
  • HY-103149
    SB-216641A

    sb-216641 hydrochloride

    		 5-HT Receptor Neurological Disease
    SB-216641A (SB-216641 hydrochloride) is a selective antagonist of 5-HT1B/D receptor. SB-216641A shows high affinity and selectivity for h5-HT1B receptors over h5-HT1D receptors. SB-216641A inhibits the function of SKF-99101H .
    SB-216641A
  • HY-10847B
    SB-277011 hydrochloride
    1 Publications Verification

    sb-277011A hydrochloride

    		 Dopamine Receptor 5-HT Receptor Neurological Disease
    SB-277011 hydrochloride (SB-277011A hydrochloride) is a potent, selective, orally bioavailable and brain penetrate dopamine D3 receptor (D3R) antagonist with Ki values of 10.7 nM and 11.2 nM at rodent and human D3R, respectively. SB-277011 hydrochloride displays 80- to 100-fold selectivity over other dopamine receptors with pKis of 8.0, 6.0, <5.2, and 5.9 for D3, D2, 5-HT1B, and 5-HT1D receptors, respectively .
    SB-277011 hydrochloride
  • HY-70068
    SB-408124

    		Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-408124 is a non-peptide OX1 receptor antagonist with Kis of 57 nM and 27 nM in whole cell and membrane, respectively. SB-408124 exhibits 50-fold selectivity over OX2 receptor .
    SB-408124
  • HY-16981
    SB-332235

    		CXCR Inflammation/Immunology
    SB-332235 is a potent, orally active nonpeptide CXCR2 antagonist, with an IC50 of 7.7 nM. SB-332235 displays 285-fold selectivity for CXCR2 over CXCR1. SB-332235 inhibits acute and chronic models of arthritis in the rabbit. SB-332235 inhibits viability of AML cells .
    SB-332235
  • HY-112349
    SB 203580 sulfone

    		Drug Derivative Interleukin Related Lipoxygenase Inflammation/Immunology
    SB 203580 sulfone is an analog of p38 MAP kinase inhibitor SB 203580. SB 203580 sulfone inhibits the IL-1 production (IC50 of 0.2 μM in monocytes) and binds competitively with CSAID binding proteins (CSBP), inhibits it mediated stress response signaling with an IC50 of 0.03 μM. SB 203580 sulfone inhibits 5-LO with an IC50 value of 24 µM. SB 203580 sulfone can be used in the research of inflammatory diseases .
    SB 203580 sulfone
  • HY-108333
    SB-633825
    4 Publications Verification

    		 Ser/Thr Kinase Cardiovascular Disease Cancer
    SB-633825 is a potent and ATP-competitive inhibitor of TIE2, LOK (STK10) and BRK with IC50s of 3.5 nM, 66 nM, 150 nM, respectively. SB-633825 can inhibit cancer cell growth and angiogenesis .
    SB-633825
  • HY-18618A
    SB-612111 hydrochloride
    2 Publications Verification

    		 Opioid Receptor Neurological Disease Inflammation/Immunology
    SB-612111 hydrochloride hydrochloride is a novel and potent opiate receptor-like orphan receptor (ORL-1) antagonist with a high affinity for hORL-1 (Ki=0.33 nM). SB-612111 hydrochloride exhibits selectivity for μ-,?κ- and?δ-receptors with Ki values of?57.6 nM, 160.5 nM and 2109 nM, respecticely. SB-612111 hydrochloride effectively antagonizes the pronociceptive action of Nociceptin (HY-P0183) in an acute pain model .
    SB-612111 hydrochloride
  • HY-103099
    SB-399885 hydrochloride
    1 Publications Verification

    		 5-HT Receptor Neurological Disease
    SB-399885 hydrochloride is a 5-HT6 receptor antagonist.
    SB-399885 hydrochloride
  • HY-122891
    SB02024
    1 Publications Verification

    		 PI3K CXCR STAT Cancer
    SB02024 is a potent and orally active VPS34 inhibitor. SB02024 inhibits Vps34 kinase activity. SB02024 induces CCL5 and CXCL10 via STAT1/IRF7. SB02024 shows anticancer activity .
    SB02024
  • HY-119017
    SB-429201

    		HDAC Cancer
    SB-429201 is a potent and selective HDAC1 (IC50~1.5 μM). SB-429201 displays at least a 20-fold preference for HDAC1 inhibition over HDAC3 and HDAC8 .
    SB-429201
  • HY-112291
    SB 220025

    		p38 MAPK Src PKC Inflammation/Immunology
    SB 220025 is a reversible, orally active, cell-permeable, ATP-competitive and selective human p38 MAPK inhibitor (IC50 = 60 nM). SB 220025 also inhibits p56 Lck and PKC with IC50 values of 3.5 and 2.89 µM, respectively. SB 220025 inhibits the expression of IL-8 gene in response to globular adiponectin (gAd), reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 effectively prevents the progression of arthritis in a chronic inflammatory disease model and can be used in the study of inflammation .
    SB 220025
  • HY-103123
    SB 258719 hydrochloride

    		5-HT Receptor Neurological Disease Cancer
    SB 258719 hydrochloride is a selective 5-HT7 receptor antagonist displayed high affnity (pKi=7.5) for the receptor. SB-258719 hydrochloride can be used for the research of cancer and neurological diseases .
    SB 258719 hydrochloride
  • HY-10657
    SB-706375

    		Urotensin Receptor Cardiovascular Disease Others
    SB-706375 is an antagonist of the Urotensin II (UII) receptor. By blocking the Urotensin II receptor, SB-706375 reduces the kidney's response to UII and Urotensin-related peptide (URP) and significantly increases the Glomerular Filtration Rate (GFR). SB-706375 can be used in research on kidney diseases and hypertension .
    SB-706375
  • HY-103141
    SB-258585 hydrochloride

    		5-HT Receptor Neurological Disease
    SB-258585 is a high affinity ligand for the 5-HT6 receptor. SB-258585 binds highly to a single receptor population in a human cell line that recombines 5-HT6 receptors. SB-258585 can be used to label recombinant and natural 5-HT6 receptor .
    SB-258585 hydrochloride
  • HY-114038
    SB-747651A

    		p38 MAPK Inflammation/Immunology
    SB-747651A is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC50 of 11 nM. SB-747651A also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A can be used for inflammation research .
    SB-747651A
  • HY-135439
    SB-203186

    		5-HT Receptor Neurological Disease
    SB-203186 is a highly selective 5-HT4 receptor antagonist. SB-203186 exhibits a potent competitive antagonistic effect, with its pKB value being 8.3 in the isolated right atrium model of piglets. SB-203186 can dose-dependently shift the 5-HT-induced tachycardia curve to the right, and does not inhibit the maximum response. SB-203186 is an efficient 5-HT₄ antagonist in pig and human atria, but has no significant inhibitory effect in rat atria. SB-203186 can be used for the study of diseases such as arrhythmias and abnormal myocardial contraction .
    SB-203186
  • HY-144898
    SB-216

    		Microtubule/Tubulin Apoptosis Cancer
    SB-216 is an BBB-penetrable tubulin polymerization inhibitor. SB-216 can inhibit the proliferation and migration, and induce apoptosis and cell cycle arrest of tumor cells. SB-216 has good in vivo metabolic stability and low toxicity, but its oral bioavailability is limited. SB-216 has antitumor activity and can be used in the research of tumors such as melanoma .
    SB-216
  • HY-171854
    SB-583355

    		G2A (GPR132) Neurological Disease Inflammation/Immunology
    SB-583355 (Compound 56) is a potent G2A antagonist. SB-583355 can be prepared by a Suzuki reaction between 4-methoxyphenyl boronic acid and 3-bromo-4-hydroxybenzoic acid following the conditions followed by an amide coupling reaction. SB-583355 blocks the activation of G2A mediated either by 9-HOPE or T-10148 in human G2A expressing CHO-K1 cells. SB-583355 can be studied in research for inflammation, myeloid leukemia, and neuropathic pain .
    SB-583355
  • HY-10847
    SB-277011

    sb-277011A

    		 Dopamine Receptor Endocrinology
    SB-277011 (SB-277011A) is a highly selective dopamine D3 receptor antagonist. SB-277011 induces ejaculation delay by inhibiting the expulsion phase of ejaculation, without impairing ejaculatory secretion or erectile function. SB-277011 also prolongs the post-ejaculatory refractory period. SB-277011 has no effect on the spontaneous preference of male rats for females in the sexually receptive phase. SB-277011 is widely applicable to studies related to premature ejaculation .
    SB-277011
  • HY-15105
    SB-423562

    		CaSR Inflammation/Immunology
    SB-423562 is a short-acting calcium-sensing receptor (CaR) antagonist. SB-423562 has the potential for osteoporosis research.
    SB-423562
  • HY-106337
    SB 247083

    		Endothelin Receptor Cardiovascular Disease
    SB 247083 is a selective, competitive and orally active endothelin-A receptor antagonist with a Ki of 0.41 nM. SB 247083 shows a Ki of 467 nM to endothelin-B receptor. SB 247083 shows a Kb of 3.5 nM for ET-1-induced contraction of rat aorta. SB 247083 can be used for the research of cardiovascular disease .
    SB 247083
  • HY-112741
    SB-209247
    1 Publications Verification

    		 Leukotriene Receptor Inflammation/Immunology
    SB-209247 is a selective, high affinity and orally active leukotriene B4 (LTB4) receptor antagonist with a Ki of 0.78 nM. SB-209247 blocks LTB4-induced Ca 2+ mobilization with an IC50 of 6.6 nM. SB-209247 shows a potent anti-inflammatory activity .
    SB-209247
  • HY-112367
    SB 202474
    1 Publications Verification

    		 p38 MAPK Cancer
    SB 202474, a negative analog of SB203580. SB 202474, which has no ability to inhibit p38 MAPK activity and is widely used as a negative control compound in p38 MAPK studies, also suppressed melanin synthesis induction .
    SB 202474
  • HY-W903631
    SB-216641

    		5-HT Receptor Neurological Disease
    SB-216641 is a selective 5-HT1b antagonist. SB-216641 mildly prevents stress-induced behavioral performance dysregulations .
    SB-216641
  • HY-116603
    SB-236057

    		5-HT Receptor Others
    SB-236057 is an inverse agonist of the 5-HT1B receptor that exhibits strong skeletal teratogenicity in rodents and rabbits. SB-236057 affects gene expression during embryonic development through interference with the Notch signaling pathway and interaction with r-esp1. SB-236057 induces somatic patterning and tail extension defects in rat embryos during early organogenesis .
    SB-236057
  • HY-76612
    SB-408124 Hydrochloride

    		Orexin Receptor (OX Receptor) Neurological Disease Endocrinology
    SB-408124 Hydrochloride is a selective non-peptide orexin receptor 1 (OX1) receptor antagonist with Kis of 57 nM and 27 nM in whole cell and membrane, respectively. SB-408124 Hydrochloride exhibits 50-fold selectivity over OX2 receptor .
    SB-408124 Hydrochloride
  • HY-105325
    SB-219994

    		PPAR Inflammation/Immunology
    SB-219994 is a peroxisome proliferator-activated receptors (PPARs) agonists. SB-219994 can inhibit airway neutrophilia and associated chemoattractants/survival factors. SB-219994 exhibits anti-inflammation effec .
    SB-219994
  • HY-18306R
    SB 242235 (Standard)

    		p38 MAPK Autophagy Cancer
    SB 242235 (Standard) is the analytical standard of SB 242235. This product is intended for research and analytical applications. SB-242235 is a potent and selective p38 MAP kinase inhibitor, with an IC50 of 1.0　μM in primary human chondrocytes .
    SB 242235 (Standard)
  • HY-124260
    SB-204900

    		p38 MAPK Inflammation/Immunology
    SB-204900 is an oxane carboxamide that can be isolated from the hexane extract of Clausena lansium. SB-204900 significantly inhibited phosphorylation of p38 MAPK. SB-204900 has anti-inflammatory activity .
    SB-204900
  • HY-10295AR
    SB 202190 hydrochloride (Standard)

    		Organoid Reference Standards p38 MAPK Autophagy Apoptosis Neurological Disease Cancer
    SB 202190 (hydrochloride) (Standard) is the analytical standard of SB 202190 (hydrochloride). This product is intended for research and analytical applications. SB 202190 hydrochloride is a selective p38 MAP kinase inhibitor with IC50s of 50 nM and 100 nM for p38α and p38β2, respectively. SB 202190 hydrochloride binds to the ATP pocket of the active recombinant human p38 kinase with a Kd of 38 nM. SB 202190 hydrochloride has anti-cancer activity . SB202190 hydrochloride induces autophagy .
    SB 202190 hydrochloride (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: